Literature DB >> 15496672

Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain.

Miguel Díaz-Hernández1, Fernando Moreno-Herrero, Pilar Gómez-Ramos, María A Morán, Isidro Ferrer, Arturo M Baró, Jesús Avila, Félix Hernández, José J Lucas.   

Abstract

Huntington's disease (HD) and eight additional inherited neurological disorders are caused by CAG triplet-repeat expansions leading to expanded polyglutamine-sequences in their respective proteins. These triplet-CAG repeat disorders have in common the formation of aberrant intraneuronal proteinaceous inclusions containing the expanded polyglutamine sequences. These aggregates have been postulated to contribute to pathogenesis caused by conformational toxicity, sequestration of other polyglutamine-containing proteins, or by interfering with certain enzymatic activities. Testing these hypotheses has been hampered by the difficulty to isolate these aggregates from brain. Here we report that polyglutamine aggregates can be isolated from the brain of the Tet/HD94 conditional mouse model of HD, by following a method based on high salt buffer homogenization, nonionic detergent extraction, and gradient fractionation. We then verified that the method can be successfully applied to postmortem HD brains. Immunoelectron microscopy, both in human and mouse samples, revealed that the stable component of the inclusions are mutant huntingtin-containing and ubiquitin-containing fibrils. Atomic-force microscopy revealed that these fibrils have a "beads on a string" morphology. Thus, they resemble the in vitro assembled filaments made of recombinant mutant-huntingtin, as well as the Abeta and alpha-synuclein amyloid protofibrils. Finally, by shutting down transgene expression in the Tet/HD94 conditional mouse model of HD, we were able to demonstrate that these filaments, although stable in vitro, are susceptible to revert in vivo, thus demonstrating that the previously reported reversal of ubiquitin-immunoreactive inclusions does not simply reflect disassembling of the inclusions into their constituent fibrils and suggesting that any associated conformational or protein-sequestration toxicity is also likely to revert.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496672      PMCID: PMC6730096          DOI: 10.1523/JNEUROSCI.2365-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  16 in total

1.  Synchrotron infrared microspectroscopy detecting the evolution of Huntington's disease neuropathology and suggesting unique correlates of dysfunction in white versus gray brain matter.

Authors:  Markus Bonda; Valérie Perrin; Bertrand Vileno; Heike Runne; Ariane Kretlow; László Forró; Ruth Luthi-Carter; Lisa M Miller; Sylvia Jeney
Journal:  Anal Chem       Date:  2011-09-22       Impact factor: 6.986

2.  TiO2 Nanoparticles as Potential Promoting Agents of Fibrillation of α-Synuclein, a Parkinson's Disease-Related Protein.

Authors:  Soheila Mohammadi; Maryam Nikkhah
Journal:  Iran J Biotechnol       Date:  2017-08-19       Impact factor: 1.671

3.  Hypertonic stress induces rapid and widespread protein damage in C. elegans.

Authors:  Kris Burkewitz; Keith Choe; Kevin Strange
Journal:  Am J Physiol Cell Physiol       Date:  2011-05-25       Impact factor: 4.249

4.  Flanking sequences profoundly alter polyglutamine toxicity in yeast.

Authors:  Martin L Duennwald; Smitha Jagadish; Paul J Muchowski; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

5.  Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.

Authors:  Sharad Gupta; Shy'Ann Jie; David W Colby
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

6.  Post-aggregation oxidation of mutant huntingtin controls the interactions between aggregates.

Authors:  Yasushi Mitomi; Takao Nomura; Masaru Kurosawa; Nobuyuki Nukina; Yoshiaki Furukawa
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

7.  Elongation kinetics of polyglutamine peptide fibrils: a quartz crystal microbalance with dissipation study.

Authors:  Robert H Walters; Kurt H Jacobson; Joel A Pedersen; Regina M Murphy
Journal:  J Mol Biol       Date:  2012-03-26       Impact factor: 5.469

Review 8.  Protein quality control in neurodegeneration: walking the tight rope between health and disease.

Authors:  E M Hol; W Scheper
Journal:  J Mol Neurosci       Date:  2007-03-24       Impact factor: 3.444

9.  Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.

Authors:  Justin Legleiter; Gregor P Lotz; Jason Miller; Jan Ko; Cheping Ng; Geneva L Williams; Steve Finkbeiner; Paul H Patterson; Paul J Muchowski
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157

10.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.

Authors:  Kirupa Sathasivam; Amin Lane; Justin Legleiter; Alice Warley; Ben Woodman; Steve Finkbeiner; Paolo Paganetti; Paul J Muchowski; Stuart Wilson; Gillian P Bates
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.